伊鲁替尼，布鲁顿酪氨酸激酶抑制剂，隐球菌病的新危险因素

IF 5 Q3 Medicine Medecine et maladies infectieuses Pub Date : 2020-11-01 DOI:10.1016/j.medmal.2020.07.005

J. Brochard , F. Morio , J. Mahe , P. Le Pape , T. Guimard , B. Mahe , M. Leterrier , M. Morrier , F. Raffi , D. Boutoille

{"title":"伊鲁替尼，布鲁顿酪氨酸激酶抑制剂，隐球菌病的新危险因素","authors":"J. Brochard , F. Morio , J. Mahe , P. Le Pape , T. Guimard , B. Mahe , M. Leterrier , M. Morrier , F. Raffi , D. Boutoille","doi":"10.1016/j.medmal.2020.07.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.</p></div><div><h3>Patients and method</h3><p>We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.</p></div><div><h3>Results</h3><p>Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.</p></div><div><h3>Conclusion</h3><p>Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.07.005","citationCount":"7","resultStr":"{\"title\":\"Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis\",\"authors\":\"J. Brochard , F. Morio , J. Mahe , P. Le Pape , T. Guimard , B. Mahe , M. Leterrier , M. Morrier , F. Raffi , D. Boutoille\",\"doi\":\"10.1016/j.medmal.2020.07.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.</p></div><div><h3>Patients and method</h3><p>We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.</p></div><div><h3>Results</h3><p>Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.</p></div><div><h3>Conclusion</h3><p>Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.</p></div>\",\"PeriodicalId\":18464,\"journal\":{\"name\":\"Medecine et maladies infectieuses\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2020-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.medmal.2020.07.005\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medecine et maladies infectieuses\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0399077X20306739\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medecine et maladies infectieuses","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0399077X20306739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 7

摘要

目的:在接受依鲁替尼(一种布鲁顿酪氨酸激酶抑制剂)治疗的血液系统恶性肿瘤患者中，侵袭性真菌疾病，特别是新型隐球菌感染的报道越来越多。患者和方法我们报告了另外3例病例，并回顾了以前发表的16例病例以及国际药物警戒数据库中的病例。结果本组患者以慢性淋巴细胞白血病为主。隐球菌病主要发生在治疗的前6个月(66%)，尤其是治疗的前2个月(44%)。临床表现通常是肺部(68%)，尽管继续使用依鲁替尼，结果通常是有利的。结论临床医生应注意依鲁替尼治疗的恶性血液病患者的这种感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis

Purpose

Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.

Patients and method

We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.

Results

Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.

Conclusion

Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Medecine et maladies infectieuses 医学-传染病学

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

10.7 weeks

期刊介绍： L''organe d''expression de la Société de Pathologie Infectieuse de Langue Française (SPILF). Médecine et Maladies Infectieuses is the official publication of the Société de Pathologie Infectieuse de Langue Française (SPILF). Médecine et Maladies Infectieuses is indexed in the major databases: Medline, Web of Science/Clarivate and Scopus. The journal publishes scientific /research articles, general reviews, short communications and letters, in both English and French. The journal welcomes submissions on the various aspects of infectious pathologies and pathogenic agents. Médecine et Maladies Infectieuses focuses on clinical therapeutics, nosocomial infections, biology, prevention, as well as epidemiology and therapeutics.